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H IV is a virus that hijacks the immune system's white blood cells and forces them to make new copies of the virus. 
Treatment with antiretroviral drugs is remarkably 
effective at suppressing replication of the virus, and 
most individuals who take antiretroviral drugs are 
able to reduce the amount of HIV circulating in their 
bloodstream to undetectable levels. However, this 
treatment cannot eliminate a small but stubborn 
population of infected white blood cells that con-
tain a copy of the virus's genetic material within 
their own genomes. These cells can persist in the 
body for life, and they allow the virus to re-emerge 
and ignite new rounds of infection if antiretroviral 
therapy (or ART) is ever interrupted. Eliminating 
these cells is the focus of an emerging global effort 
aimed at finding a cure for HIV disease.
In order to eradicate these cells, we first need 
to be able to measure them accurately. Most peo-
ple on long-term ART have about 10–1000 copies 
of HIV DNA per million white blood cells that can 
be infected by the virus (Eriksson et al., 2013). 
However, most of this ‘total HIV DNA’ is defective 
and cannot trigger new infections (See Figure 1A). 
The rare cells that appear to contain intact copies 
of the virus, which are able to replicate, are 
referred to as the ‘latent reservoir’. Moreover, 
only a fraction of the cells in the latent reservoir 
can be induced to produce new viruses in cell 
culture experiments (Ho et al., 2013). Developing 
a high-throughput method for measuring the size 
of the latent reservoir will therefore require us 
to identify a specific molecule (or biomarker) that 
distinguishes the cells in the reservoir from other 
infected cells. In the absence of such a method, 
the only way to currently determine if an interven-
tion has effectively cured a patient, and reduced 
or eliminated the reservoir, is to interrupt therapy 
under the supervision of a physician and wait until 
the virus re-emerges or ‘rebounds’ (Figure 1B). 
This approach clearly carries some risk to the 
patient (and his or her sexual partners) and is 
logistically challenging.
Now, in eLife, John Frater at the John 
Radcliffe Hospital in Oxford and co-workers in 
the SPARTAC collaboration report an important 
advance in the search for a biomarker for the 
latent reservoir. The SPARTAC study enrolled a 
cohort of individuals infected with HIV who were 
identified during the early stages of their infection. 
Subjects were randomly selected to receive either 
antiretroviral therapy for several weeks before 
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the therapy was stopped, or no antiretroviral 
therapy (which is the standard course of action for 
an early HIV infection). This study aimed to deter-
mine if short-term ART during an early infection 
preserves the function of the immune system and 
eventually allows individuals to stop therapy 
safely. As previously reported (Fidler et al., 2013), 
the SPARTAC group found that this was not the 
case, and concluded that once ART is initiated it 
should not be interrupted.
A cure—or more accurately remission (a tem-
porary end of disease symptoms)—will likely be 
defined based on how long a person remains free 
from replicating HIV in the absence of therapy. It 
is logical to predict that the smaller the HIV reser-
voir during ART, the longer it will take for the virus 
to rebound after the treatment is stopped (Hill 
et al., 2014): this idea is also supported by recent 
clinical experience (Yukl et al., 2013; Henrich 
et al., 2014; Persaud et al., 2013). A test that is 
inexpensive, sensitive and reproducible, and that 
accurately reflects the total amount of replication-
competent HIV, would therefore have profound 
effects on cure research—particularly if it could 
predict what would happen if therapy were inter-
rupted. Finding a biomarker that achieves all of 
this would allow investigators to perform efficient 
proof-of-concept studies and allow regulators to 
guide companies through the drug development 
process. Such a development would be compara-
ble to the tremendous advances in antiviral thera-
pies that were enabled by developing the HIV 
plasma viral load test, which measures how much 
virus is circulating in the bloodstream.
One way to estimate the size of the HIV latent 
reservoir would be to measure how many cells 
contain HIV DNA. In the SPARTAC study, Frater 
and co-workers—who include James Williams 
and Jacob Hurst as joint first authors—measured 
the frequency of certain white blood cells (the 
CD4+ T cells) that harbour HIV DNA (that is, the 
‘total HIV DNA’) in all the participants at the start 
of the trial. Even though it is well recognised that 
most HIV DNA is defective and unable to support 
replication, the total DNA in early untreated HIV 
infection could predict how the disease would 
progress (Williams et al., 2014). The total DNA 
declined by several fold during the course of ART, 
as expected. The total DNA prior to stopping 
ART also predicted how quickly the number of 
CD4+ T cells would decline and how quickly the 
virus would rebound. Those patients with high 
levels of total DNA had over double the rate of 
viral rebound as individuals with low levels of total 
DNA. Total HIV DNA levels can thus predict how 
long a patient can safely remain off treatment, and 
Figure 1. Identifying a biomarker for the latent reservoir of 
HIV could be used to guide future clinical trials. (A) Much 
of the HIV DNA harboured by infected cells is defective 
and cannot replicate itself, but there is a “latent 
reservoir” of intact HIV DNA that can support replication. 
However, it is difficult to measure the size of the latent 
reservoir because only a fraction of the cells in the 
reservoir can be readily induced to produce HIV in tissue 
cultures. (B) Antiretroviral therapy (or ART) can suppress 
the levels of HIV circulating in a patient's bloodstream 
(red line), below detectable levels (dashed line). 
However, the only way to currently determine whether  
a potential cure intervention (vertical black arrow) is 
effective or not is to interrupt ART and then monitor the 
amount of the virus in the blood to see if and when the 
virus ‘rebounds’. (C) Williams, Hurst et al. reveal that 
measuring the total level of HIV DNA can help predict 
the progress of an infection after ART is stopped. As 
such, total HIV DNA could be used as a predictive 
biomarker in future clinical trials testing potential cure 
interventions. The total DNA could be measured before 
a potential cure was administered, and then measured 
again some time afterwards to see if the level of total 
DNA has been decreased. Such a biomarker might 
allow clinicians to identify patients who can safely test 
cure interventions, and to select those who can safely 
interrupt their treatment if the ‘cure’ appears successful.
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may prove to be useful in monitoring potential 
cure treatments (Figure 1C). Studies to confirm 
these observations are now being planned.
Developing and evaluating possible HIV cures 
faces many challenges beyond how best to meas-
ure the reservoir. Nevertheless, there are now 
many interventions that might provide a cure, 
including early ART (Persaud et al., 2013; Saez-
Cirion et al., 2013) and drugs that essentially 
shock the virus out of hiding (Archin et al., 2012). 
Other possible cures include gene therapies 
(Tebas et al., 2014), stem cell transplantation 
(Hutter et al., 2009; Henrich et al., 2014) and 
drugs that make the patients cells less hospitable 
for the virus (Barouch and Deeks, 2014). As such, 
progress towards a cure may not have stalled 
but it is certainly being hindered by the lack of a 
robust biomarker for the HIV reservoir. The findings 
by the SPARTAC team have now helped the field 
identify a way to move forward in finding such a 
biomarker.
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